Shukra [SHUKRAPHAR] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison
Shukra
BSE
Loading...
Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Shukra wins in 9 metrics, Sun Pharma Advanced wins in 8 metrics, with 0 ties. Shukra appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Shukra | Sun Pharma Advanced | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 83.45 | -13.50 | Sun Pharma Advanced |
| Price-to-Book Ratio | 13.11 | -21.28 | Sun Pharma Advanced |
| Debt-to-Equity Ratio | 6.65 | -1.24 | Sun Pharma Advanced |
| PEG Ratio | N/A | 2.57 | N/A |
| EV/EBITDA | 49.17 | -17.26 | Sun Pharma Advanced |
| Profit Margin (TTM) | 26.02% | -53.22% | Shukra |
| Operating Margin (TTM) | 53.21% | -568.05% | Shukra |
| EBITDA Margin (TTM) | 53.21% | N/A | N/A |
| Return on Equity | 15.90% | 157.88% | Sun Pharma Advanced |
| Return on Assets (TTM) | 10.58% | -102.08% | Shukra |
| Free Cash Flow (TTM) | $51.75M | $-3.71B | Shukra |
| Dividend Yield | 7.26% | N/A | N/A |
| 1-Year Return | 193.29% | -33.23% | Shukra |
| Price-to-Sales Ratio (TTM) | 21.85 | 71.84 | Shukra |
| Enterprise Value | $8.33B | $48.95B | Sun Pharma Advanced |
| EV/Revenue Ratio | 22.63 | 75.78 | Shukra |
| Gross Profit Margin (TTM) | 86.72% | -10.68% | Shukra |
| Revenue per Share (TTM) | $1 | $2 | Sun Pharma Advanced |
| Earnings per Share (Diluted) | $0.22 | $-9.18 | Shukra |
| Beta (Stock Volatility) | 0.33 | 0.31 | Sun Pharma Advanced |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Shukra vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Shukra | -1.98% | -9.47% | -9.78% | 51.86% | -16.36% | 28.30% |
| Sun Pharma Advanced | -0.14% | -4.17% | -10.63% | -4.18% | -4.98% | -29.04% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Shukra | 193.29% | 295.69% | 1,717.82% | 1,019.51% | 394.88% | 394.88% |
| Sun Pharma Advanced | -33.23% | -41.02% | -21.77% | -65.52% | 48.73% | -51.01% |
Performance & Financial Health Analysis: Shukra vs Sun Pharma Advanced
| Metric | SHUKRAPHAR | SPARC |
|---|---|---|
| Market Information | ||
| Market Cap | ₹8.04B | ₹46.41B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 91,148 | 245,429 |
| 90 Day Avg. Volume | 190,256 | 361,227 |
| Last Close | ₹18.36 | ₹142.41 |
| 52 Week Range | ₹5.75 - ₹27.15 | ₹109.30 - ₹241.00 |
| % from 52W High | -32.38% | -40.91% |
| All-Time High | ₹27.15 (Mar 03, 2025) | ₹875.00 (Apr 24, 2006) |
| % from All-Time High | -32.38% | -83.72% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.30% | -0.43% |
| Quarterly Earnings Growth | 0.35% | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | -0.53% |
| Operating Margin (TTM) | 0.53% | -5.68% |
| Return on Equity (TTM) | 0.16% | 1.58% |
| Debt to Equity (MRQ) | 6.65 | -1.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹1.40 | ₹-6.69 |
| Cash per Share (MRQ) | ₹0.27 | ₹0.06 |
| Operating Cash Flow (TTM) | ₹79.18M | ₹-3,484,287,000 |
| Levered Free Cash Flow (TTM) | ₹41.04M | ₹-3,425,094,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 7.26% | N/A |
| Last 12-Month Dividend | ₹1.00 | N/A |
Valuation & Enterprise Metrics Analysis: Shukra vs Sun Pharma Advanced
| Metric | SHUKRAPHAR | SPARC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 83.45 | -13.50 |
| Forward P/E | N/A | 2.57 |
| PEG Ratio | N/A | 2.57 |
| Price to Sales (TTM) | 21.85 | 71.84 |
| Price to Book (MRQ) | 13.11 | -21.28 |
| Market Capitalization | ||
| Market Capitalization | ₹8.04B | ₹46.41B |
| Enterprise Value | ₹8.33B | ₹48.95B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 22.63 | 75.78 |
| Enterprise to EBITDA | 49.17 | -17.26 |
| Risk & Other Metrics | ||
| Beta | 0.33 | 0.31 |
| Book Value per Share (MRQ) | ₹1.40 | ₹-6.69 |
Financial Statements Comparison: Shukra vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SHUKRAPHAR | SPARC |
|---|---|---|
| Revenue/Sales | ₹132.70M | ₹96.40M |
| Cost of Goods Sold | ₹17.63M | ₹106.70M |
| Gross Profit | ₹115.07M | ₹-10.30M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹63.76M | ₹-547.60M |
| EBITDA | ₹87.85M | ₹-429.40M |
| Pre-Tax Income | ₹75.70M | ₹-518.10M |
| Income Tax | ₹21.84M | ₹600,000 |
| Net Income (Profit) | ₹53.86M | ₹-518.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SHUKRAPHAR | SPARC |
|---|---|---|
| Cash & Equivalents | N/A | ₹19.64M |
| Total Current Assets | ₹654.27M | ₹261.97M |
| Total Current Liabilities | ₹172.84M | ₹3.74B |
| Long-Term Debt | ₹31.13M | ₹1.07B |
| Total Shareholders Equity | ₹628.36M | ₹-2.17B |
| Retained Earnings | N/A | ₹-23.22B |
| Property, Plant & Equipment | ₹193.97M | ₹178.02M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SHUKRAPHAR | SPARC |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SHUKRAPHAR | SPARC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 91,148 | 245,429 |
| Average Daily Volume (90 Day) | 190,256 | 361,227 |
| Shares Outstanding | 437.88M | 324.52M |
| Float Shares | 47.92M | 91.74M |
| % Held by Insiders | 0.89% | 0.73% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Shukra vs Sun Pharma Advanced
| Metric | SHUKRAPHAR | SPARC |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | N/A |
| Last 12-Month Dividend Yield | 7.26% | N/A |
| 3-Year Avg Annual Dividend | ₹0.35 | N/A |
| 3-Year Avg Dividend Yield | 5.23% | N/A |
| 3-Year Total Dividends | ₹1.04 | N/A |
| Ex-Dividend Date | Sep 23, 2024 | N/A |